223 related articles for article (PubMed ID: 32410259)
21. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
22. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
[TBL] [Abstract][Full Text] [Related]
24. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine O; Jiang L; Walewski J; Bosly A; Thieblemont C; Szymczyk M; Pott C; Salles G; Feugier P; Hübel K; Haioun C; Casasnovas RO; Schmidt C; Bouabdallah K; Ribrag V; Kanz L; Dürig J; Metzner B; Sibon D; Cheminant M; Burroni B; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Dreyling M;
J Clin Oncol; 2023 Jan; 41(3):479-484. PubMed ID: 36469833
[No Abstract] [Full Text] [Related]
25. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
[TBL] [Abstract][Full Text] [Related]
26. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
27. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K; Yamaguchi M; Atsuta Y; Matsue K; Sato K; Kusumoto S; Nagai H; Takizawa J; Fukuhara N; Nagafuji K; Miyazaki K; Ohtsuka E; Okamoto M; Sugita Y; Uchida T; Kayukawa S; Wake A; Ennishi D; Kondo Y; Izumi T; Kin Y; Tsukasaki K; Hashimoto D; Yuge M; Yanagisawa A; Kuwatsuka Y; Shimada S; Masaki Y; Niitsu N; Kiyoi H; Suzuki R; Tokunaga T; Nakamura S; Kinoshita T
Lancet Oncol; 2020 Apr; 21(4):593-602. PubMed ID: 32171071
[TBL] [Abstract][Full Text] [Related]
28. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
29. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.
Arranz R; García-Noblejas A; Grande C; Cannata-Ortiz J; Sánchez JJ; García-Marco JA; Aláez C; Pérez-Calvo J; Martínez-Sánchez P; Sánchez-González B; Canales MA; Conde E; Martín A; Arranz E; Terol MJ; Salar A; Caballero D
Haematologica; 2013 Oct; 98(10):1563-70. PubMed ID: 23753021
[TBL] [Abstract][Full Text] [Related]
30. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
Kahl BS; Longo WL; Eickhoff JC; Zehnder J; Jones C; Blank J; McFarland T; Bottner W; Rezazedeh H; Werndli J; Bailey HH;
Ann Oncol; 2006 Sep; 17(9):1418-23. PubMed ID: 16766582
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score.
Khouri IF; Saliba RM; Okoroji GJ; Acholonu SA; Champlin RE
Cancer; 2003 Dec; 98(12):2630-5. PubMed ID: 14669282
[TBL] [Abstract][Full Text] [Related]
32. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.
Lossos IS; Hosein PJ; Morgensztern D; Coleman F; Escalón MP; Byrne GE; Rosenblatt JD; Walker GR
Leuk Lymphoma; 2010 Mar; 51(3):406-14. PubMed ID: 20038221
[TBL] [Abstract][Full Text] [Related]
33. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Thomas D; O'Brien S; Faderl S; Ravandi F; Jabbour E; Pierce S; Cortes J; Kantarjian H
Cancer; 2010 Oct; 116(19):4580-9. PubMed ID: 20572037
[TBL] [Abstract][Full Text] [Related]
34. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
Khouri IF; Romaguera J; Kantarjian H; Palmer JL; Pugh WC; Korbling M; Hagemeister F; Samuels B; Rodriguez A; Giralt S; Younes A; Przepiorka D; Claxton D; Cabanillas F; Champlin R
J Clin Oncol; 1998 Dec; 16(12):3803-9. PubMed ID: 9850025
[TBL] [Abstract][Full Text] [Related]
35. R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
Alderuccio JP; Saul EE; Iyer SG; Reis IM; Alencar AJ; Rosenblatt JD; Lossos IS
Am J Hematol; 2021 Jun; 96(6):680-689. PubMed ID: 33735476
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
37. The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation.
Broccoli A; Argnani L; Gugliotta G; Pellegrini C; Casadei B; Bagnato G; Gentilini M; Stefoni V; Zinzani PL
Oncologist; 2024 Jun; 29(6):e789-e795. PubMed ID: 38339976
[TBL] [Abstract][Full Text] [Related]
38. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
Le Gouill S; Thieblemont C; Oberic L; Moreau A; Bouabdallah K; Dartigeas C; Damaj G; Gastinne T; Ribrag V; Feugier P; Casasnovas O; Zerazhi H; Haioun C; Maisonneuve H; Houot R; Jardin F; Van Den Neste E; Tournilhac O; Le Dû K; Morschhauser F; Cartron G; Fornecker LM; Canioni D; Callanan M; Béné MC; Salles G; Tilly H; Lamy T; Gressin R; Hermine O;
N Engl J Med; 2017 Sep; 377(13):1250-1260. PubMed ID: 28953447
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
[TBL] [Abstract][Full Text] [Related]
40. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
Jacobsen E; Freedman A
Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
